Elliot is Director of Business Development at Stabilitech Biopharma Ltd and is responsible for leading commercial activities on their development pipeline which includes a super-seasonal influenza vaccine, orally delivered vaccines and therapeutic candidates, and a thermal stability platform for viruses. Elliot is also focused on identifying new targets for Stabilitech’s novel oral vaccine platform.
Formerly at Queen Mary Innovation Ltd, Elliot managed the commercialisation of life-science projects from Queen Mary University of London. Partnering with industry, he enabled the development and commercialisation of cutting edge science, generating revenues for the university and its inventors. He also produced non-clinical regulatory packages, preclinical toxicity plans and conducted scientific advice meetings with the MHRA. He now holds an honorary fellowship position at the university.
Four years prior, Elliot was responsible for global business development at SLA Pharma Ltd, out-licensing a Phase III gastrointestinal treatment to a pan-European company.
Elliot received a PhD in ‘The immunomodulatory properties of oligosaccharides’ in 2002.